Tracking the evolution of non–small-cell lung cancer
…, PA Crosbie, B Naidu, G Middleton… - … England Journal of …, 2017 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …
The interplay of immunotherapy and chemotherapy: harnessing potential synergies
LA Emens, G Middleton - Cancer immunology research, 2015 - AACR
Although cancer chemotherapy has historically been considered immune suppressive, it is
now accepted that certain chemotherapies can augment tumor immunity. The recent success …
now accepted that certain chemotherapies can augment tumor immunity. The recent success …
[HTML][HTML] Capecitabine and oxaliplatin for advanced esophagogastric cancer
…, M Nicolson, F Coxon, G Middleton… - … England Journal of …, 2008 - Mass Medical Soc
Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum
compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated …
compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated …
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
…, A Marie Quinn, PA Crosbie, B Naidu, G Middleton… - Nature, 2017 - nature.com
The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …
the characterization of emerging subclones, which seed metastatic sites, might offer new …
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an …
G Middleton, P Silcocks, T Cox, J Valle… - The Lancet …, 2014 - thelancet.com
Background We aimed to assess the efficacy and safety of sequential or simultaneous
telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally …
telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally …
[HTML][HTML] Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre …
…, P Lind, B Glimelius, S Falk, JR Izbicki, GW Middleton… - The Lancet, 2017 - thelancet.com
Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients …
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients …
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Background Individuals with cancer, particularly those who are receiving systemic anticancer
treatments, have been postulated to be at increased risk of mortality from COVID-19. This …
treatments, have been postulated to be at increased risk of mortality from COVID-19. This …
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study
The importance of intratumour genetic and functional heterogeneity is increasingly recognised
as a driver of cancer progression and survival outcome. Understanding how tumour …
as a driver of cancer progression and survival outcome. Understanding how tumour …
The National Lung Matrix Trial of personalized therapy in lung cancer
The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed
against oncogenic drivers that are more prevalent in patients with light exposure to tobacco …
against oncogenic drivers that are more prevalent in patients with light exposure to tobacco …
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
…, J Prausova, HJ Lenz, C Borg, G Middleton… - Journal of clinical …, 2008 - ascopubs.org
Purpose To determine whether adding cetuximab to irinotecan prolongs survival in patients
with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and …
with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and …